Emergent Biosolutions INC 10-Q quarterly reports

Emergent BioSolutions reported a significant increase in operating income for the nine months ended September 30, 2025, driven by cost reductions and strategic divestitures, despite a decline in overall revenue.

Emergent BioSolutions Inc. reported a significant turnaround to net income and positive cash flow in Q2 2025, driven by cost reductions and strategic divestitures, despite a decline in total revenues.

Emergent BioSolutions announces its Q1 2025 financial results, highlighting increased net income and strategic moves including the sale of the Baltimore-Bayview facility and a new share repurchase program.

Emergent BioSolutions reports a net income of $114.8 million for Q3 2024, a significant turnaround from a net loss of $263.4 million in the same period last year, driven by increased MCM product sales and strategic divestitures.

Emergent BioSolutions reported a net loss of $274.1 million for the second quarter of 2024, impacted by restructuring charges and declining product sales, while also navigating significant debt and going concern issues.

Emergent BioSolutions saw a significant increase in revenue in the first quarter of 2024, driven by strong sales of MCM products and NARCAN, while also navigating ongoing restructuring efforts and financial challenges.